期刊文献+

肝素在肿瘤治疗中的应用 被引量:3

Application of heparin in cancer therapy
原文传递
导出
摘要 肝素作为传统抗凝剂已众所周知。研究发现,肝素尚具有多种生物学活性,特别是抗肿瘤作用备受学者关注。尽管临床上并未将肝素疗法作为一种常规抗肿瘤手段,但是许多研究已经证明了肝素能够抑制肿瘤细胞的侵袭与转移。本文综述肝素治疗肿瘤的主要机制以及肝素结构修饰在抗癌方面的应用。 Heparin is widely used clinically as an anticoagulant. It is reported that heparin contains a variety of biological activities. Specially, the antitumor activity has attracted much attention. While heparin has not been used for anticancer clinically. Numerous studies have demonstrated that heparin could inhibit the invasion and metastasis of cancer cells. This article will summarize the antitumor mechanism of heparin and anticancer effect of the surface modified heparin.
作者 李涵 崔慧斐
出处 《生命的化学》 CAS CSCD 2014年第1期109-114,共6页 Chemistry of Life
关键词 肝素 抗肿瘤 结构修饰 heparin anticancer structural modification
  • 相关文献

参考文献32

  • 1Pisano C, Aulicino C, Vesci L, et al. Low-molecular- weight glycol-split heparin as an antiangiogenetic VEGF antagonist. Glycobiology, 2005, 15:1-6. 被引量:1
  • 2Takahashi H, Ebihara S, Okazaki T, et al. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor- induced tumor angiogenesis and heparanase activity. Br J Pharmacol, 2005, 146:333-343. 被引量:1
  • 3Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res, 2007, 120 (Suppl 2): S 107-S 111. 被引量:1
  • 4Chalkiadaki G, Nikitovic D, Katonis P, et al. Low molecular weight heparin inhibits melanoma cell adhesion and migration through a Pka/JNK signaling pathway including actin cytoskeleton changes. Cancer Lett, 2011, 312:235-244. 被引量:1
  • 5Mellor P, Harvey JR, Murphy KJ, et al. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth ofLMD MDA-MB 231 breast cancer ceils in vivo. Br J Cancer, 2007, 97: 761-768. 被引量:1
  • 6Loureiro RM, D'Amore PA. Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev, 2005, 16:77-89. 被引量:1
  • 7Moran MS, Yang Q, Goyal S, et al. Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys, 2011, 81:1236-1243. 被引量:1
  • 8Ji W, Yang J, Wang D, et al. hSulf-I gene exhibits anticancer efficacy through negatively regulating VEGFR-2 signaling in human cancers. PLoS One, 2011, 6(8): e23274. 被引量:1
  • 9Guo S, Colbert LS, Fuller M, et al. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta, 2010, 1806:108-121. 被引量:1
  • 10Cassinelli G, Lanzi C, Tortoreto M, et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol, 2013, 85:1424-1432. 被引量:1

同被引文献4

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部